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(Figure 1).
Methods, Intervention, & Analysis: As the storm ap-
proached, interdisciplinary teams discharged many patients
hospital-wide, however the BMTU patients were deemed
unable to discharge. Private HEPA ﬁltered rooms were
blocked on the regular oncology unit as reserve in case the
BMTU became compromised. Nurses followed procedures for
blackout and computer down time; including the printing of
essential information from the electronic medical record
(EMR). Once power and communication systems failed,
nurses and other interdisciplinary team members safely
evacuated patients using med sled evacuation devices and
necessary equipment for monitoring and support down
sixteen ﬂights of dark stairwells to waiting ambulances. To
ensure safe transfer and a hand-off report to the receiving
hospital, nurses accompanied all BMTU patients. Hand-off
communication was also accomplished centrally from the
HICS using the previously printed EMR summaries (Figure 2).
Findings & Interpretation: A total of four patients, including
one autologous transplant patient and patients with
chemotherapy infusing, were transported to a neighboring
hospital without interruption of care. Staff relied on prior
disaster training, expert clinical judgment, and emotional
intelligence to accomplish this unprecedented task.
Discussion & Implications: Disaster training and drills are
vital to developing the skills needed during an emergency.
Nurses, as ﬁrst responders, lead in times of disaster. The ef-
forts of this team demonstrate what can be accomplished
when everyone is well trained and focused on the same goal,
patient safety.502
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Topic Signiﬁcance & Study Purpose/Background/Rationale:
Plerixafor (MOZOBIL) is an antagonist of alpha-chemokine
receptor CXCR and one of the recent additions to the Hae-
matology discipline; it is used as a stem cell mobiliser. CXCR4
alpha-chemokine receptors are important in hematopoietic
stem cells homing to the bone marrow and in hematopoietic
stem cell quiescence. It is indicated in combination with
Granulocyte Colony Stimulating Factor (GCSF) for Peripheral
Blood Stem Cell (PBSC) collections in the Multiple Myeloma
(MM) and Lymphoma patient groups with a poor mobi-
lisation history.
Methods, Intervention, & Analysis: Method In our organi-
sation, data was collected prospectively. 35 patients (two
patients were included twice as they received Prelixafor on
two separate occasions) received Plerixafor for PBSC collec-
tion between May 2009 and September 2012. Patients met
the criteria prior to treatment, except three patients with low
platelet counts (white Blood Count> 2.5 x 109/L, Absolute
Neutrophil Count > 1.5 x 109/L, Platelet> 85 x 109/L, Serum
Creatinine < 1.5 mg/dL, Aspartate transaminase (AST),
Alanine Transaminase (ALT), Bilirubin < 2 x ULN with no
evidence of Hepatitis B and C. Patient demographic data is
shown in Table 1. Five patients had an underlying docu-
mented medical problem (cortochondritis, asthma, hyper-
tension and glaucoma).
Findings & Interpretation: Result: 25 of the patients were
diagnosed with MM and six with Non-Hodgkin’s Lymphoma
(NHL), two patients had Hodgkin’s Disease, one had Neuro-
blastoma and one Walderstorm’s Macroglobulinameia. All
patients received four consecutive days of GCSF 10 mg/kgprior to Plerixafor. Plerixafor was given 10 hours before the
PBSC collection and GCSF was repeated one hour prior to
PBSC collection on the morning. All patients received 0.24
mg/kg/day of Plerixafor. There were no side effects observed
in these episodes. 26 patients required single dose, 10 pa-
tients required a second dose, and only one patient received
three dose of Plerixafor.
For all cases, the target CD34+ count was 4 x 106 cells/kg
of recipient body weight. Two patients responded extremely
well with a CD34+ count of 21.79 x 106 cells/kg and 15.16
x106 cells/kg achieved. 13 patients achieved the target of 4
X106 cells/kg or above. However 22 patients failed to achieve
to reach target. 16 of these patients had adequate amounts of
CD34 count for an autologous transplant. Four patient failed
to mobilise with CD 34+ <2 X109cells/kg. Only six patient
had > CD 34+ <2 X109cells/kg one of this patient had no
CD34+ at all.
Discussion & Implications: Conclusion Plerixafor was used
at The London Clinic recently with mostly favourable out-
comes. According to this study Plerixafor has improved PBSC
outcomes with some exceptions. Plerixafor has deﬁnitely
made a positive difference in 40% of our patients and 83% had
enough cells for an autologus transplant. However, results
are inconclusive due to small patient numbers. Ongoing
studies with new patient experiences are needed. More than
one dose of Plerixafor may be required for heavily pre-
treated patients who are historically poor mobilisers of PBSC
collections.503
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Topic Signiﬁcance & Study Purpose/Background/Rationale:
Introduction Over the last decade, information for cancer
patients has become increasingly more available. The very
nature of cancer requires patients to learn about their disease
in order to copewith the consequences of treatment and to be
involved in decision making processes. It is therefore vital to
provide enough information for patients and their relevant
others. People/patients vary in the amount of information
they require. Evidence suggests that some patients do not
want very much information about their diseases and treat-
ments. This study aims to explore howmuch information our
patient group wants to know and howmuch information our
team provides.
Methods, Intervention, & Analysis: Method A question-
naire was prepared to collect data on howmuch information
was given to patients on three different stages of their
treatment plans. These stages were: on admission, during
their inpatient stay and on discharge. A fourth section was
added, to investigate other information that patient felt
would be beneﬁcial. 112 questionnaires were given between
May 2010 and October 2012, outcome data is shown in Table
I. Stage Information provided on the following topics N, %
On admission
1. Side effects of therapy or chemotherapy 39 (34.8%)
2. Procedures (Bone Marrow Aspiration, Hickman Line
insertion etc) 35(31.2%)
3. Sexuality 11(9.8%)
4. Fertility 13(11.6%)
5. Results of diagnostic test 49(43.7%)
6. Follow up, appointments 39(34.8%)
7. Diet 23(20.5%) other 0(0%)
